Skip to main content
Premium Trial:

Request an Annual Quote

Deltagen and Pfizer Sign Gene Function Database Agreement

NEW YORK, Dec 22 - Deltagen said Friday that it has signed Pfizer as the second licensee to its DeltaBase gene function database.

Under the terms of the agreement, Pfizer will have non-exclusive access to in vivo mammalian gene function information on 750 genes in DeltaBase, as well as access to corresponding DeltaBase intellectual property rights.

The initial term of the agreement is three years, through June 30, 2003, with the option to extend the term for two additional years. Pfizer will have access to 250 genes per year.

Pfizer elected to license all previous data releases under DeltaBase. Deltagen will receive $15 million in license access fees, with up to $25 million possible with term extensions. Other financial terms of the agreement were not disclosed.

“We believe that DeltaBase will become an integral part of the pharmaceutical R&D process by providing researchers with the capacity to translate raw genomic sequence into information on the function, disease relevance and potential commercial value of a particular gene," said Bill Matthews, president and CEO of Deltagen, in a statement.

DeltaBase contains functional and phenotypic information for genes that have been chosen for their ability to be useful targets for drug discovery.

Deltagen signed Glaxo Wellcome as its first DeltaBase subscriber in September under similar terms.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.